15 Sep

What Analysts Recommend for Sage Therapeutics

WRITTEN BY Mike Benson

Sage Therapeutics’ valuation

Sage Therapeutics (SAGE) is a clinical-research-based biopharmaceutical company focused on developing drugs for life-threatening central nervous system disorders like postpartum depression, Parkinson’s disease, and others.

What Analysts Recommend for Sage Therapeutics

The above chart shows analysts’ recommendations for Sage Therapeutics over the last 12 months. The company hasn’t generated any revenues from product sales since inception nor does the company expect to generate any revenues from product sales in the near future.

Analysts’ recommendations

Sage Therapeutics’ stock price has risen nearly 54.5% over the last 12 months, while the analysts estimate the stock has a potential to return 30.3% over the next 12 months. Wall Street analysts’ recommendations show a 12-month targeted price of $83.69 per share as compared to the last price of $70.37 per share as of September 13, 2017. In comparison, 13 analysts are tracking Merck’s stock. Of these, 11 analysts recommend a “buy,” while two analysts recommend a “hold.” The consensus rating on Sage Therapeutics stock is 1.7, which represents a buy for both momentum investors and long-term investors.

Analysts’ estimates

Sage Therapeutics’ stock price has risen nearly 54.5% over the last 12 months, while the analysts estimate the stock has a potential to return 30.3% over the next 12 months. Wall Street analysts estimate a net loss of $75.3 million during 3Q17 and a net loss of $79.1 million during 4Q17. No revenues are expected from product sales in the next few quarters.

To divest company-specific risks, investors can consider ETFs like the Vanguard Healthcare ETF (VHT), which holds 0.1% of its total assets in Sage Therapeutics. VHT also holds 3.0% in Celgene (CELG), 1.8% in Biogen (BIIB), and 3.1% in AbbVie (ABBV).

Latest articles

Broadcom (AVGO) stock fell ~8.5% after markets closed yesterday following the semiconductor giant's fiscal 2019 second-quarter earnings release. It missed analysts' revenue estimate and cut its fiscal 2019 revenue guidance by $2 billion to $22.5 billion due to sluggishness in its semiconductor solutions business.

The SPDR Gold Shares ETF (GLD), which tracks physical gold prices, has underperformed the broader markets year-to-date, rising just 4.4% compared to the S&P 500’s (SPY) gain of 15.9% as of June 14. The sentiment for gold, however, has been turning around.

Safe havens such as Treasuries and gold were back in favor on June 14 as stocks fell due to rising tensions in the Middle East, concerns over growth, and the looming threat of the US-China trade war. The tech-heavy Nasdaq Composite Index fell 0.67% in the first hour of trading.

Lululemon (LULU) stock rose 2.1% on June 13 in reaction to better-than-expected first-quarter results and an upgraded outlook for fiscal 2019 overall. The company's first-quarter adjusted EPS grew 34.5% to $0.74 on revenue growth of 20.4% to $782.32 million. Analysts had expected EPS of $0.70 and revenue of $755.31 million. Here's why the outlook got an upgrade.

14 Jun

IEA Again Slashes Its Oil Demand Growth Estimate

WRITTEN BY Rabindra Samanta

As of 4:40 AM Eastern Time today, US crude oil active futures were at $51.83, ~4% below their closing level in the previous week. If US crude oil prices stay at those levels today, they'll mark their third week of decline in five weeks.

Amazon is discontinuing its Amazon Restaurants service, which has been delivering food for restaurants in parts of the United States. Amazon Restaurants launched in the United States in 2015 and entered the British market the following year. However, it met strong opposition in the British market.

172.31.71.127